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Objective: The cardio-ankle vascular index (CAVI) is a novel and accurate method, independent of the
effect of blood pressure, and is used as a predictor of arterial stiffness (AS). However, the application of
CAVI to identify the prevalence and clinical correlates of AS in peritoneal dialysis (PD) patients remains
under investigation. The objective of this study was to explore the clinical correlates of PD patients with
AS diagnosed by the CAVI examination compared with PD patients without AS.
Materials and Methods: A total of 50 patients who had undergone PD for more than 3 months were
enrolled in this cross-sectional study. AS was deﬁned as a CAVI 9. The clinical correlations between
CAVI and AS in PD patients were studied.
Results: These PD patients had a high prevalence (42%) of AS. Age, systolic blood pressure, history of
cardiovascular disease, hematocrit, glucose level, and phosphorus level were positively correlated
with AS in PD patients compared with those without AS. Furthermore, multivariate regression analysis
showed that age [adjusted odds ratio (OR)¼ 1.116, p¼ 0.010]; systolic blood pressure (adjusted
OR¼ 1.080, p¼ 0.010); hematocrit (adjusted OR¼ 1.896, p¼ 0.006); and history of cardiovascular disease
(adjusted OR¼ 35.492, p¼ 0.013) were all independently correlated with AS in PD patients.
Conclusion: The prevalence of AS in PD patients was high. Older age, elevated systolic blood pressure,
hematocrit, and history of cardiovascular disease were positively related to the AS process shown by CAVI
assessment in PD patients. However, further studies are needed to elucidate these factors, especially the
hematocrit, affecting AS in PD patients after long-term follow-up.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Cardiovascular mortality is very predominant in renal failure
patients, especially in those on chronic dialysis [1]. One cause of
cardiovascular mortality in dialysis patients is arterial stiffness (AS)
[2]. The causal risk of AS in dialysis patients can be brieﬂy divided
into two principal types of factors: (1) well-deﬁned factors, such
as aging, hypertension, hyperphosphatemia, hypercalcemia, and
hyperparathyroidism; and (2) other aggravated factors, including
malnutrition; lower fetuin-A levels; increased homocysteine,
ﬁbroblast growth factor-23, and endogenous nitric oxide synthesis
inhibitor (asymmetric dimethylarginine) levels; hepatitis Cy, Buddhist Tzu Chi General
alien, Taiwan. Tel.: þ886 3
ang).
ddhist Compassion Relief Tzu Chiinfection; use of beta-blockers; and so on [3e5]. Therefore, the
clinical correlates of AS in dialysis patients have been investigated.
The traditional assessment of AS in dialysis patients uses
brachial-ankle pulse wave velocity (baPWV) [6,7]. Disappointedly,
the actual evaluation of the baPWV is inﬂuenced by a changeable
blood pressure during measurement [8]. Emerging data have
veriﬁed that the cardio-ankle vascular index (CAVI), a novel and
noninvasive method, is an accurate parameter of AS independent
of the effect of blood pressure [9,10]. For example, the CAVI has
been used as a clinical parameter of AS in patients with essential
hypertension [11], diabetes mellitus [12], obesity and metabolic
syndrome [13], and end-stage renal disease (ESRD) [9,14].
CAVI has been proved to be better than baPWV in assessing AS in
dialysis patients [9,14], suggesting that this is a superior screening
test to detect AS in dialysis patients. However, the clinical correlates
of AS using CAVI assessment in peritoneal dialysis (PD) patients
remain under investigation. The objective of this study was toFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of peritoneal dialysis patients with and without arterial stiffness
Without arterial
stiffness
(n¼ 29)
With arterial
stiffness
(n¼ 21)
p
Age (y) 45.3 2.7 60.1 2.5 <0.001
Gender 0.647
Male 7 10
Female 22 11
Height (cm) 157.9 1.7 158.2 2.0 0.900
Body weight (kg) 59.1 2.3 59.0 2.5 0.979
BMI (kg/m2) 23.6 0.8 23.6 0.8 0.992
Waist circumference (cm) 86.2 1.9 89.8 1.9 0.197
SBP (mmHg) 120.8 4.1 140.3 6.7 0.012
DBP (mmHg) 73.8 2.4 81.4 3.4 0.066
Duration of dialysis (y) 3.0 0.6 3.9 1.2 0.479
Thyroidectomy 0.647
Yes 4 2
No 25 19
Primary causes of ESRD 0.064
DM 4 7 0.120
GN 18 5
HTN 3 1
Others 4 8
Smoking history 0.647
Yes 4 2
No 25 19
Metabolic syndrome 0.152
Yes 12 13
No 17 8
Clinical symptoms and signs of PAOD 0.349
Yes 10 10
No 19 11
History of CVD 0.006
Yes 2 8
No 27 13
Vitamin D agents 0.815
Yes 12 8
No 17 13
Antihypertensive agents 0.726
Yes 18 12
No 11 9
Lipid-lowering agents 0.390
Yes 16 9
No 13 12
Hypoglycemic agents 0.724
Yes 7 6
No 22 15
Data are presented as n or mean standard deviation.
BMI¼ body mass index; CVD¼ cardiovascular disease; DBP¼ diastolic blood
pressure; DM¼ diabetes mellitus; ESRD¼ end-stage renal disease; GN¼ glomer-
ulonephritis; HTN¼ hypertension; PAOD¼ peripheral artery occlusive disease;
SBP¼ systolic blood pressure.
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by a CAVI examination, compared with those in PD patients
without AS.
2. Materials and methods
2.1. Patient characteristics
All experimental procedures were carried out in accordance
with and after the approval from the Ethics Committee and Human
Subjects Institutional Review Board of Tzu Chi Hospital, Hualien. All
patients were carefully instructed with respect to the study details,
and written informed consent was obtained from each participant.
A total of 50 uremic patients undergoing continuous ambulatory
PD (CAPD) for more than 3 months were studied in this cross-
sectional study in April 2009. Patients on CAPD exchanged 2 L of
dialysate containing 1.5%, 2.5%, or 4.25% glucose four times per day.
Patients with acute illness were excluded from the study. Patient
characteristics and medical history were obtained from direct
interview or medical records, including age; gender; height; body
weight; smoking habits; primary causes of ESRD; duration of
dialysis; history of cardiovascular disease (CVD), diabetes, hyper-
tension, and peripheral arterial occlusive disease; and use of anti-
hypertensive, hypoglycemic, and lipid-lowering agents and vitamin
D. The body mass index (kg/m2) was calculated according to the
standard formula. Waist circumference was measured midway
between the inferior margin of the last rib and the top of the hip
bone on a transverse plane. The adequacy of dialysis, such as
fractional urea clearance (Kt/V), weekly creatinine clearance, and
normalized protein catabolic rate, was also evaluated.
To manage disturbances in mineral and bone metabolism
[calcium (Ca), phosphorus (P), and intact parathyroid hormone] in
PD subjects, we treated patients according to the 2003 Kidney
Disease Outcomes Quality Initiative clinical practice guidelines
for bone metabolism and disease in chronic kidney disease [15].
Additionally, patients received recombinant erythropoietin
(rHuEpo) tomaintain their hematocrit levels between 33% and 36%,
based on Kidney Disease Outcomes Quality Initiative clinical
practice guidelines and clinical practice recommendations for
anemia in chronic kidney disease [16]. Patients regularly took iron
and vitamin supplements.
2.2. Measurement of CAVI
CAVI was measured in each patient. A CAVI 9 was deﬁned as
the threshold value for AS, in agreement with that by Shirai et al [9]
and with the instructions of the manufacturer of the equipment
(VaSera VS-1000; Fukuda Denshi, Tokyo, Japan). According to the
protocol, the patients rested in the supine position for at least 10
minutes before measurements were performed. Cuffs were applied
to the four extremities, and electrocardiographic electrodes were
attached to the upper extremities. A microphone was placed on the
sternal angle for phonocardiography. The CAVI was automatically
calculated using a waveform analyzer present in the equipment
[9,17]. The completemeasurement of the CAVI was usually achieved
in less than 5 minutes.
2.2.1. Blood biochemistry and hematological assays
Blood was drawn from a peripheral vein after overnight fasting.
Twelve milliliters of blood was taken from each patient before
dialysis; 2 mL of whole blood was used for the measurement of the
hematocrit using a Sysmex XE-2100, an automated analyzer (Sys-
mex, Kobe, Japan), and the remaining 10 mL was immediately
centrifuged at 3000 g for 15 minutes, and the serum was stored at
4C within 1 hour after collection for further examinations.Serum levels of glucose, albumin, uric acid, total cholesterol,
high-density-lipoprotein cholesterol, triglycerides, total Ca, P, and
high-sensitivity C-reactive protein were measured with a Cobas
Integra 800 analyzer (Roche Diagnostics, Indianapolis, IN, USA).
Serum total homocysteine and intact parathyroid hormone levels
were measured by an automated chemiluminescence immuno-
assay by means of an Advia Centaur Analyzer (Siemens, Muenchen,
Germany) [18].
2.3. Statistical analysis
Data were expressed as either case numbers or means
standard deviation. Student t test was applied to compare the
Table 3
Multivariate stepwise logistic regression analysis of risk factors for arterial stiffness
Variables Adjusted OR 95% CI p
Age 1.116 1.011e1.233 0.010
SBP 1.080 1.018e1.145 0.010
Hct level 1.896 1.201e2.991 0.006
History of CVD 33.492 2.101e533.941 0.013
Constant 0.000 0.002
Dependent variable: arterial stiffness diagnosed by cardio-ankle vascular index.
Independent variables: age, SBP, history of CVD, hematocrit, glucose, and phos-
phorus.
CI¼ conﬁdence interval; CVD¼ cardiovascular disease; Hct¼ hematocrit;
OR¼ odds ratio; SBP¼ systolic blood pressure.
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using Chi-square analysis or Fisher’s exact test. Statistical signiﬁ-
cance was deﬁned as a p value <0.05. All statistically signiﬁcant
variables (p< 0.05) were entered into a multivariate stepwise
logistic regression model as independent variables, and AS was
used as a dependent variable. All statistical analyses were per-
formed with SPSS, version 13.0 (SPSS Inc., Chicago, IL, USA).
3. Results
The clinical characteristics of PD patients with and without AS
are presented in Table 1. The prevalence rate of AS in these PD
patients was 42% (21 of 50). PD patients with AS were older
(p< 0.001) and had a higher systolic blood pressure (SBP)
(p¼ 0.012) than those without AS. Additionally, a history of CVD
was correlated with AS (p¼ 0.006). There were no signiﬁcant
differences in body weight; body mass index; waist circumference;
height; diastolic blood pressure; duration of dialysis; smoking
history; primary causes of ESRD; metabolic syndrome; clinical
symptoms and signs of peripheral arterial occlusive disease; and
the administration of antihypertensive, hypoglycemic, or lipid-
lowering agents between groups.
Table 2 shows the clinical biochemistries of PD patients with
and without AS. There were signiﬁcantly higher hematocrits
(p¼ 0.033), glucose levels (p¼ 0.046), and P levels (p¼ 0.020) in PD
patients with AS than in those without AS. Furthermore, there were
no signiﬁcant differences in albumin, uric acid, total cholesterol,
triglycerides, high-density-lipoprotein cholesterol, intact para-
thyroid hormone, Ca, Ca P product, total homocysteine, high-
sensitivity C-reactive protein, Kt/V, weekly creatinine clearance, or
normalized protein catabolic rate between groups.
Multivariate stepwise logistic regression analysis in PD patients
with AS is summarized in Table 3. Age, SBP, history of CVD,
hematocrit, glucose level, and P level were taken as independent
variables, and AS, as assessed by CAVI, was taken as the dependent
variable. Multivariate logistic regression analysis for risk factors in
PD patients with AS showed that age [adjusted odds ratio (OR)¼
1.116, p¼ 0.010]; SBP (adjusted OR¼ 1.080, p¼ 0.010); hematocritTable 2
Clinical biochemistries of peritoneal dialysis patients with and without arterial
stiffness
Without arterial
stiffness (n¼ 29)
With arterial
stiffness (n¼ 21)
p
EPO amounts (U/mo) 15,200 2539 16,500 1250 0.225
Hct (%) 30.1 0.7 32.6 0.9 0.033
Glucose (mg/dL) 109.4 7.7 150.8 21.3 0.046
Albumin (g/dL) 3.8 0.1 3.5 0.1 0.087
Uric acid (mg/dL) 6.8 0.2 6.7 0.2 0.862
Total cholesterol (mg/dL) 208.8 9.6 180.7 10.9 0.060
TG (mg/dL) 240.8 43.1 178.5 27.7 0.272
LDL-C (mg/dL) 107.2 20.5 97.6 18.6 0.112
HDL-C (mg/dL) 51.1 4.0 50.1 5.0 0.878
iPTH (pg/mL) 454.8 89.9 338.1 99.9 0.394
Corrected Ca (mg/dL) 9.1 0.2 9.4 0.2 0.326
P (mg/dL) 5.5 0.2 4.7 0.2 0.020
Ca P product (mg2/dL2) 50.2 2.4 44.6 2.2 0.108
T-Hcy (mmol/L) 37.6 8.3 26.3 2.5 0.264
hs-CRP (mg/dL) 1.0 0.3 1.5 0.4 0.393
Kt/V 2.1 0.1 2.0 0.1 0.123
WCC (L/wk/1.73 m2) 62.9 3.1 65.6 2.8 0.534
nPNA (g/kg/d) 1.0 0.0 0.9 0.0 0.099
Ca¼ calcium; EPO¼ recombinant erythropoietin; Hct¼ hematocrit; HDL-C¼ high-
density lipoprotein cholesterol; hs-CRP¼ high-sensitivity C-reactive protein;
iPTH¼ intact parathyroid hormone; Kt/V¼ fractional urea clearance; LDL-C¼ low-
density lipoprotein cholesterol; nPNA ¼ normalized protein nitrogen appearance;
P¼ phosphorus; TG¼ triglycerides; T-Hcy¼ total homocysteine; WCC¼weekly
creatinine clearance.(adjusted OR¼ 1.896, p¼ 0.006); and history of CVD (adjusted
OR¼ 33.492, p¼ 0.013) were deﬁnitely related to AS in PD patients.
4. Discussion
Information about the application of CAVI to evaluate risk
factors of AS in PD patients remains limited. In this study, it was
well established that PD patients have a high incidence of AS (42%),
and older age, elevated SBP, higher serum hematocrit, and history
of CVD were independent risk correlates of AS by CAVI examination
in PD patients. Only age and elevated SBP were traditional inde-
pendent risks correlated with AS in PD patients. The other tradi-
tional risk factors (e.g. diabetes mellitus and total cholesterolemia)
did not show a signiﬁcant contribution to AS in PD patients. The
reasons are unclear. Possibly, the small case number might have
made some traditional risk factors become insigniﬁcant or cause
nontraditional risk factors to becomemore prominent in this study.
Studies have shown that aging can cause aortic stiffness in
healthy individuals [19] and dialysis patients [14,20], similar to the
results in this study. Aging causes remodeling of arteries. This
process activates the upregulation of Type 2 matrix metal-
loproteinase in the aorta of rats and humans, causing intimal and
medial thickening, vessel luminal dilation, fragmentation of the
elastic membrane, and increased AS [21,22].
In our results, an elevated SBP was positively associated with AS
in PD patients, consistent with reports in hemodialysis [20] and
hypertensive patients [23]. A clinical study has suggested that
achieving an optimal SBP in renal failure patients attenuates the
process of AS [24]. Many uremic patients with AS have an elevated
SBP, which induces a vicious cycle [25]. An elevated SBP leads to
vessel hypertrophy, loss of elasticity, and arterial stiffening [26].
The hematocrit in our study was a signiﬁcant factor affecting AS
in multiple regression models; the PD patients with AS had higher
hematocrits and higher SBPs than PD patients without AS because
patients in the AS group received more rHuEpo than those without
AS. In contrast, patients in the AS group still had a greater anemia
level compared with the general population owing to ESRD-related
effects. This result is consistent with a study which showed that AS
in patients with cyanotic congenital heart disease is affected by
arterial pressure and anemia [27]. The exact mechanisms for this
observation between AS and the hematocrit are unknown. Two
explanations are possible. First, anemia itself activates the sympa-
thetic nervous system to cause heart failure and AS [28]. Second,
rHuEpo is used for the treatment of renal anemia in dialysis
patients, and this treatment might induce greater systemic vascular
resistance either by the rise of erythrocyte mass or the change in
various endogenous vasopressors, including the direct action of
rHuEpo itself [29]. These effects may be the cause of hypertension
and the AS process. Therefore, in our study, the AS group had
episodic anemia and received more rHuEpo; these factors may
combine to evoke the development of vascular disorders and AS.
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ascertained in long-term studies.
Our recent study showed that de novo AS, as determined by
CAVI, in chronic dialysis patients was signiﬁcantly associated with
age and initial serum P after a 1-year follow-up [30]. Along with the
focal process of atherosclerosis (mainly affecting the intima of the
arteries), the diffuse pathological phenomenon of arteriosclerosis
(affecting mainly the media of large- and middle-sized arteries) is
prominent in chronic dialysis patients with CVD [5]. In this aspect,
endothelial dysfunction, atheroma, oxidative stress, vascular
calciﬁcation, and AS are closely related. Pathologically, chronic
hypercalcemia impairs endothelium-dependent vasodilatation,
accelerates deposition of Ca in the media and intima of the vascular
wall and in individual myocardial ﬁbers (dystrophic calciﬁcation),
increases intima-media thickness of the artery walls, damages
vascular compliance and capacitance, and induces development of
AS [31]. Therefore, our study suggested that a history of CVD in PD
patients is a major risk factor for AS.
In conclusion, our study demonstrates that these PD patients
had a high prevalence of AS by CAVI assessment (42%, 21 of 50).
Age, SBP, hematocrit, and history of CVD are closely associated with
AS in PD patients. Age, SBP, and history of CVD are well-known
predisposing factors. However, further studies of the hematocrit
are needed to elucidate these factors affecting AS in long-term
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